ReviewAuto- immunity highlights2011
Pathophysiology of the antiphospholipid antibody syndrome.
Review in Auto- immunity highlights, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 72 citations in OpenAlex.
- Serum from Patients with Antiphospholipid Syndrome Differentially Affects Venous and Microcirculatory Endothelial Cells.Biology · 2026Article
- Longitudinal profiling of antiphospholipid antibodies reveals pre-conception levels as a key predictor of live birth in women with recurrent pregnancy loss.Frontiers in immunology · 2026Article
- Upper Extremity Deep Vein Thrombosis in the Setting of Ductal Carcinoma In Situ: A Case Report.Cureus · 2024Article
- The Etiology of the Thrombotic Phenomena Involved in the Process of Coronary Artery Disease-What Is the Role of Thrombophilic Genes in the Development of This Pathology?International journal of molecular sciences · 2024Review
- Position Statement on Ischemic Heart Disease - Women-Centered Health Care - 2023.Arquivos brasileiros de cardiologia · 2023Article
- Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE.Rheumatology (Oxford, England) · 2023Article
- Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts.Journal of clinical medicine · 2023Review
- A Retrospective Assessment of Thrombophilia in Pregnant Women with First and Second Trimester Pregnancy Loss.International journal of environmental research and public health · 2022Observational
- Emerging Therapies in Antiphospholipid Syndrome.Transfusion medicine reviews · 2022Review
- Relationship of interferon regulator factor 5 and interferon-γ with missed abortion.Experimental and therapeutic medicine · 2022Article
- Article
- Antiphospholipid Syndrome in a Patient With Autosomal Dominant Polycystic Kidney Disease: The Surface of the Moon.Cureus · 2022Article
- Oxidative Stress in the Pathogenesis of Antiphospholipid Syndrome: Implications for the Atherothrombotic Process.Antioxidants (Basel, Switzerland) · 2021Review
- Review
- miR-19b-3p and miR-20a-5p are associated with the levels of antiphospholipid antibodies in patients with antiphospholipid syndrome.Rheumatology international · 2021Observational
- Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.Journal of neurology · 2021Article
- Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals.Rheumatology (Oxford, England) · 2021Observational
- Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.Journal of thrombosis and thrombolysis · 2021Article
- Case of catastrophic antiphospholipid syndrome presenting as neuroretinitis and vaso-occlusive retinopathy.BMC ophthalmology · 2020Article
- Large Vessel Occlusion Secondary to COVID-19 Hypercoagulability in a Young Patient: A Case Report and Literature Review.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid antibodies (aPL) are associated with the recurrent pregnancy loss and thrombosis that characterizes the antiphospholipid antibody syndrome (APS). Although the ontogeny of these pathogenic antibodies has not been fully elucidated, there is evidence that indicates the involvement of both genetic and environmental factors. The ability of aPL to induce a procoagulant phenotype in APS patients plays a central role in the development of arterial and venous thrombotic manifestations typical of the disease. Inflammation serves as a necessary link between this procoagulant phenotype and actual thrombus development and is an important mediator of the placental injury seen in APS patients with obstetric complications. Recent evidence has indicated a role for abnormal cellular proliferation and differentiation in the pathophysiology of APS, especially in those patients with pregnancy morbidity and other more atypical manifestations that have no identifiable thrombotic cause. The interplay of genetic and environmental factors responsible for aPL development and the mechanisms by which these antibodies produce disease in APS patients is the focus of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.